Please assess the completion status of the following clinical trial:

Trial Title: Study of Antithymocyte Globulin for Treatment of New-onset T1DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 1 diabetes (according to American Diabetes Association \[ADA\] criteria) within100 days of enrollment~* Positive for one or more autoantibodies (anti-glutamic acid decarboxylase \[GAD\], anti-insulin, or IA-2 autoantibodies)~* Peak stimulated C-peptide level \>0.4 pmol/mL or \>1.2ng/mL following an MMTT~* Serologic evidence of prior Epstein-Barr virus (EBV) infection (EBV seropositive)~* Willing to use acceptable forms of contraception~Exclusion Criteria:~* Any sign of active infection (e.g., hepatitis, tuberculosis, EBV, cytomegalovirus (CMV), or toxoplasmosis) at screening~* Positive for human immunodeficiency virus (HIV), tuberculosis, or hepatitis B surface antigen (HBsAg) at screening~* Prior history of any significant cardiac disease, such as congestive heart failure, arrhythmia, or structural defects, or suspicion thereof~* Use of glucocorticoids in the 28 days prior to study entry; or topical use of glucocorticoids~* Use of diabetes medications (other than insulin) that may affect glucose homeostasis, such as metformin, sulfonylureas, thiazolidinediones, or amylin~* Evidence of liver dysfunction~* Evidence of kidney disease~* Pregnancy or plan to become pregnant~* Leukopenia (\<3,000 leukocytes/µL), neutropenia (\<1,500neutrophils/µL), lymphopenia (\<800 lymphocytes/µL), or thrombocytopenia (\<125,000 platelets/µL).~* Prior treatment with rabbit ATG or known hypersensitivity or exposure to rabbit sera-derived products~* Vaccination with a live virus within the last 6 weeks before enrollment~* Prior or current therapy that is known to cause a significant, ongoing change in the course of T1DM or immunologic status~* Any condition that may compromise study participation or may confound the interpretation of the study results

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Antithymocyte globulin (Type: EXPERIMENTAL): This group received a total of 6.5 mg/kg of antithymocyte globulin (e.g., Thymoglobulin®) divided into four doses as follows: Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
- Placebo (Type: PLACEBO_COMPARATOR): This group received a saline solution to match the Thymoglobulin doses given to the active treatment group, on Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).